[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"dacryocystitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:dacryocystitis":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,88],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":4},"100631712","phase-4-hyaluronic-acid-vs-mitomycin-c-in-external-dacryocystorhinostomy-100631712",false,"NCT07504250","Hyaluronic Acid vs Mitomycin-C in External Dacryocystorhinostomy","Efficacy of Hyaluronic Acid as Intraoperative Adjuvant in External Dacryocystorhinostomy Compared to Mitomycin-C: A Randomized Controlled Trial","HAM-DCR","Inclusion Criteria:\n\n1. All patients within age group 18-65 years diagnosed with chronic dacryocystitis due to Primary Acquired Nasolacrimal Duct Obstruction (PANDO) qualifying for external dacryocystorhinostomy\n2. Patients with resolved acute dacryocystitis\n\nExclusion Criteria:\n\n1. Acute dacryocystitis\u002F Lacrimal sac abscess\n2. Secondary NLDO conditions such as infections, inflammatory, traumatic, malignant, etc.\n3. Failed\u002F recurrent\u002F revision dacryocystorhinostomy and previous dacryocystectomy\n4. Presence of systemic diseases affecting wound healing (eg: uncontrolled diabetes, autoimmune conditions, etc.)\n5. Use of topical or systemic steroids\u002F immunosuppressants within 1 month prior to surgery\n6. Pregnant or lactating women\n7. Known allergy or hypersensitivity to MMC or HA.\n8. Inadequate tear volume for biomarker analysis or poor sample quality.\n9. Intraoperative flap complications\u002F excessive bleeding\n10. Blood stained discharge or bloody regurgitation\n11. Cervical or generalized lymphadenopathy\n12. Dry eyes","ALL","18 Years","65 Years",{"count":21,"type":22},36,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","RCT to compare the surgical success in patients undergoing external dacryocystorhinostomy with intraoperative Mitomycin-C (0.4 mg\u002Fml) Vs Hyaluronic acid 1% (1ml) as adjuvant, To compare the complication rates and wound healing patterns in each group, To Compare change in tear MMP-9 levels from preoperative (within 1 week before surgery) to postoperative (6 weeks after surgery) , To compare the comfort levels of patients in each group.",[28],"Dacryocystitis",[28,30,31,32],"dacryocystorhinostomy","mitomycin C","hyaluronic acid","NOT_YET_RECRUITING","2026-03-27",{"date":36,"type":37},"2026-03-31","ACTUAL",{"date":39,"type":22},"2026-04-01",{"date":41,"type":22},"2027-12-31",{"name":43,"class":44},"All India Institute of Medical Sciences, Bhubaneswar","OTHER",{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":53,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":68,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":87},"100603365","my-eyes-my-light-amar-chokh-amar-alo-100603365","NCT07135570","\"My Eyes, My Light\": Amar Chokh, Amar Alo","Stop Blindness in Coastal Bangladesh: Testing the Effectiveness of Community-Based, Artificial Intelligence-Assisted Eye Disease Screening in Coastal Bangladesh","ACA2","Inclusion Criteria:\n\n* Age 35+ years\n* Residing in the Sub-District of Char Fasson in the Bhola District\n\nExclusion Criteria:\n\n* Known eye disease diagnosis",true,"35 Years",{"count":56,"type":22},20000,"OBSERVATIONAL","Eye disease affects 2.2 billion people globally, which in turn adversely affects schooling, economic productivity, and participation in social life. The primary conditions contributing to visual impairment and blindness include cataracts, age-related macular degeneration (AMD), glaucoma, diabetic retinopathy (DR), refractive error, and presbyopia. Early detection of eye disease can provide substantial benefits in prompting treatment to reduce progression and mitigate disability.\n\nCompared with other regions, South Asia has the most cases of visual impairment due to cataracts and uncorrected refractive error. The combination of poverty, poor living and working environments, and limited health care access have long endangered eye health in Bangladesh. Coastal Bangladesh is particularly impacted by eye disease due to economic deprivation and limited healthcare access. The coastal population mostly works in fishing and agriculture, have prolonged sunlight exposure, and inadequate occupational eye protection. This low-lying region, with 35 million people, is especially vulnerable to climate disasters and global warming. High rates of chronic disease, especially diabetes mellitus Type 2 and hypertension, coupled with limited screening and treatment, shape the area's health profile, with the increasing prevalence of eye diseases such as DR, glaucoma, and visual impairment.\n\nTo address the issues of poor health, accessibility, and affordability of eye care, Artificial Intelligence (AI) applications, such as Artificial Intelligence (AI)-assisted fundus imaging, can be applied in eye screening. Medical AI applications have the potential to improve the quality and efficiency of healthcare, reduce healthcare costs, optimize treatment plans, and bolster the development of primary healthcare. They can identify presumptive DR, hypertensive retinopathy (HR), AMD, and glaucoma by analyzing the retina and optic disc of fundus images with moderate accuracy and high efficiency, thus helping address the lack of local eye care professionals.\n\nData Yakka developed a human-AI collaboration that delivers affordable and transformative community-based eye screening to underserved communities in the coastal Bangladesh region of Char Fasson. The \"Amar Chokh Amar Alo\" (My Eyes, My Light) initiative creates and implements comprehensive eye screening that combines AI-assisted eye screening and grassroots partnerships with trusted non-health non-governmental organizations (NGOs). It has three objectives: 1) Enhancing accessibility and affordability of eye screening; 2) Supporting high quality and efficient treatment of those problems detected via screening, 3) Collecting fundus images to refine or train AI algorithms in the future. This project was designed to evaluate the feasibility, performance, equity, and cost of this model of eye screening and its implications for global eye disease.\n\nThe implementation of participant recruitment, data collection, screening, and follow-up was separated into twelve steps. This standardized framework ensured the integration of screening with data collection and follow-up eye care services. Based on risk stratification by diabetes, hypertension, age 50+ years, and\u002For optometrist recommendation, fundus imaging was offered selectively to higher-risk patients.",[60,61,62,63,64,65,66,67,28],"Glaucoma","Diabetic Retinopathy (DR)","Hypertensive Retinopathy","Cataract","AMD - Age-Related Macular Degeneration","Presbyopia","Myopia","Hyperopia",[69,70,71,72,73,74,75],"vision care","eye disease screening","cataracts","glaucoma","age-related macular degeneration","refractive error","Bangladesh","RECRUITING","2025-08-19",{"date":79,"type":37},"2025-08-22",{"date":81,"type":37},"2025-01-05",{"date":83,"type":22},"2026-06",{"name":85,"class":86},"Data Yakka, Inc.","INDUSTRY",1,{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":4,"eligibilityCriteria":94,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":95,"targetDuration":4,"studyType":23,"phases":97,"briefSummary":98,"conditions":99,"keywords":102,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":87},"100490250","phase-4-does-topical-ophthalmic-proparacaine-05-prior-to-probing-and-irrigation-decrease-pain-100490250","NCT05663684","Does Topical Ophthalmic Proparacaine 0.5% Prior to Probing and Irrigation Decrease Pain?","Does Administration of Proparacaine Hydrochloride 0.5% Ophthalmic Solution Prior to Canalicular Probing and Irrigation Decrease Patient Discomfort?","Inclusion Criteria:\n\n* Participants of any sex aged 18 years or older\n* Signs and symptoms of epiphora which necessitate performance of a diagnostic probing and irrigation of the bilateral lower eyelid lacrimal drainage system at Louisiana State University Health Sciences Center or any of the listed physician offices who present with a complaint of epiphora from either eye\n\nExclusion Criteria:\n\n* A known allergy to topical proparacaine hydrochloride\n* Known pre-existing scarring, surgery, radiation to the nasolacrimal system\n* Presence of blockage and or reflux on probing and irrigation of either side\n* Cognitive Impairment",{"count":96,"type":22},145,[25],"Purpose: It is unknown whether instillation of a drop of anesthetic ophthalmic solution into the eye such as proparacaine hydrochloride 0.5% prior to probing and irrigation of the tear duct (lacrimal drainage) system improves participant comfort during the procedure. To date, there have been no formal studies evaluating the possible benefit of this pretreatment.\n\nMethods: Participants 18 years and older who present to the Louisiana State University or associated outpatient ophthalmology clinic(s) with a complaint of epiphora (excessive tearing) who necessitate bilateral lower lid probing and irrigation of the lacrimal drainage system will be enrolled in the study. One eye will be randomized to receive a drop of the anesthetic Proparacaine hydrochloride 0.5% and the other eye will receive a control drop of Balanced Salt Solution (BSS). Probing and irrigation will then be performed in the usual fashion. The participant will then be questioned via survey on a pain scale of 1-5 as to the amount of subjective pain experienced on each side during the procedure.\n\nExpected Results: Investigators expect participants will experience statistically significantly less pain in eyes that have received a drop of Proparacaine hydrochloride 0.5% prior to performance of probing and irrigation compared to the eyes which have received the control drop.",[100,101,28],"Epiphora","Dacryostenosis",[103,104],"Nasolacrimal duct obstruction","Probe and irrigation","2022-12-15",{"date":107,"type":37},"2022-12-23",{"date":109,"type":37},"2020-06-30",{"date":111,"type":22},"2023-01-31",{"name":113,"class":44},"Louisiana State University Health Sciences Center in New Orleans"]